150 related articles for article (PubMed ID: 20854187)
1. Soluble receptors for vascular endothelial growth factor (sVEGFR1/sVEGFR2) in infantile hemangioma.
Przewratil P; Sitkiewicz A; Andrzejewska E
Growth Factors; 2010 Dec; 28(6):417-25. PubMed ID: 20854187
[TBL] [Abstract][Full Text] [Related]
2. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism.
Emanuele E; Orsi P; Barale F; di Nemi SU; Bertona M; Politi P
Clin Biochem; 2010 Feb; 43(3):317-9. PubMed ID: 19850021
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report.
Przewratil P; Sitkiewicz A; Wyka K; Andrzejewska E
Pediatr Dermatol; 2009; 26(4):399-404. PubMed ID: 19689513
[TBL] [Abstract][Full Text] [Related]
5. Minimally invasive colon resection for malignant colonic conditions is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery.
Shantha Kumara HM; Cabot JC; Hoffman A; Luchtefeld M; Kalady MF; Hyman N; Feingold D; Baxter R; Whelan RL
Surg Endosc; 2010 Feb; 24(2):283-9. PubMed ID: 19551437
[TBL] [Abstract][Full Text] [Related]
6. Comparison of serum VEGF and its soluble receptor sVEGFR1 with serum cell-free DNA in patients with breast tumor.
El Tarhouny S; Seefeld M; Fan AX; Hahn S; Holzgreve W; Zhong XY
Cytokine; 2008 Oct; 44(1):65-9. PubMed ID: 18691902
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women.
Molskness TA; Stouffer RL; Burry KA; Gorrill MJ; Lee DM; Patton PE
Hum Reprod; 2004 Apr; 19(4):822-30. PubMed ID: 15033950
[TBL] [Abstract][Full Text] [Related]
8. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
9. Expression, localization and systemic concentration of vascular endothelial growth factor (VEGF) and its receptors in patients with ulcerative colitis.
Frysz-Naglak D; Fryc B; Klimacka-Nawrot E; Mazurek U; Suchecka W; Kajor M; Kurek J; Stadnicki A
Int Immunopharmacol; 2011 Feb; 11(2):220-5. PubMed ID: 21115119
[TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating vascular endothelial growth factor and its soluble receptors in adults with dengue virus infection: a case-control study.
Seet RC; Chow AW; Quek AM; Chan YH; Lim EC
Int J Infect Dis; 2009 Sep; 13(5):e248-53. PubMed ID: 19261502
[TBL] [Abstract][Full Text] [Related]
11. Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth.
Przewratil P; Sitkiewicz A; Andrzejewska E
Cytokine; 2010 Feb; 49(2):141-7. PubMed ID: 20015661
[TBL] [Abstract][Full Text] [Related]
12. Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.
Jaroszewicz J; Januszkiewicz M; Flisiak R; Rogalska M; Kalinowska A; Wierzbicka I
Cytokine; 2008 Oct; 44(1):14-7. PubMed ID: 18656381
[TBL] [Abstract][Full Text] [Related]
13. Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients.
Kikuchi S; Obata Y; Yagyu K; Lin Y; Nakajima T; Kobayashi O; Kikuichi M; Ushijima R; Kurosawa M; Ueda J
Cancer Sci; 2011 Apr; 102(4):866-9. PubMed ID: 21219538
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease.
Pohl-Schickinger A; Koehne P; Schmitz T; Schmitt KR; Hübler M; Redlin M; Berger F; Stiller B
Cardiol Young; 2010 Oct; 20(5):505-8. PubMed ID: 20470449
[TBL] [Abstract][Full Text] [Related]
16. Minimally invasive colon resection is associated with a transient increase in plasma sVEGFR1 levels and a decrease in sVEGFR2 levels during the early postoperative period.
Shantha Kumara HM; Cabot JC; Hoffman A; Luchtefeld M; Kalady MF; Hyman N; Feingold D; Baxter R; Whelan RL
Surg Endosc; 2009 Apr; 23(4):694-9. PubMed ID: 19184203
[TBL] [Abstract][Full Text] [Related]
17. Peripheral blood concentrations of vascular endothelial growth factor and its soluble receptors (R1 and R2) in patients with adrenal cortex tumours treated by surgery.
Jurczyńska J; Stepień T; Lawnicka H; Stepień H; Krupiński R; Kołomecki K; Kuzdak K; Komorowski J
Endokrynol Pol; 2009; 60(1):9-13. PubMed ID: 19224499
[TBL] [Abstract][Full Text] [Related]
18. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
Aref S; El Sherbiny M; Goda T; Fouda M; Al Askalany H; Abdalla D
Hematology; 2005 Apr; 10(2):131-4. PubMed ID: 16019458
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
20. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
